Clinical efficacy of alendronate in treatment of elderly diabetic patients complicated with osteoporosis
Received:June 24, 2019  
View Full Text  View/Add Comment  Download reader
DOI:10.11915/j.issn.1671-5403.2019.11.179
Key words:aged  alendronate sodium  diabetes mellitus  osteoporosis Corresponding author:ZHANG Qian, E-mail:inwsuwk@163.com〖FL
Author NameAffiliationE-mail
ZHANG Qian Department of Spinal Surgery, Shandong Provincial Liaocheng Second People′s Hospital, Liaocheng 252601, China inwsuwk@163.comclinical 
LYU Ling-Yan Department of Spinal Surgery, Shandong Provincial Liaocheng Second People′s Hospital, Liaocheng 252601, China inwsuwk@163.comclinical 
HU Gui-Hai Department of Spinal Surgery, Shandong Provincial Liaocheng Second People′s Hospital, Liaocheng 252601, China inwsuwk@163.comclinical 
HOU Xue-Quan Department of Spinal Surgery, Shandong Provincial Liaocheng Second People′s Hospital, Liaocheng 252601, China inwsuwk@163.comclinical 
LIU Shi-Mao Department of Spinal Surgery, Shandong Provincial Liaocheng Second People′s Hospital, Liaocheng 252601, China inwsuwk@163.comclinical 
Hits: 850
Download times: 762
Abstract:
      Objective To observe the clinical effect of alendronate sodium in the treatment of senile diabetes mellitus complicated with osteoporosis. Methods A total of 100 elderly diabetes mellitus patients complicated with senile osteoporosis admitted in our hospital from June 2017 to December 2018 were recruited in this study, and according to the parity order of their hospitalized admision, they were assigned into control group and treatment group, with 50 cases in each group. The control group were given conventional treatment, and the treatment group were given same treatment and oral administration of alendronate sodium phosphonic acid for 3 months. Bone metabolism markers, type Ⅰ collagen cross-linked aminoterminus peptide (NTXI), type Ⅰ collagen cross-linked carboxyl terminus peptide (CTXI), anti-tartaric acid phosphatase 5b (TRACP5b), blood osteocalcin (BGP), and bone alkaline phosphatase (BALP) and bone mineral density (BMD) were detected in the 2 groups before and after treatment to compare the clinical treatment effect. SPSS statistics 18.0 was used for data analysis. Results The overall response rate was significantly higher in the treatment group than in the control group (92.0% vs 64.0%, P<0.05). There were no significant differences in NTXI, CTXI, TRACP5b, BGP, BMD and BALP between the 2 groups before treatment (P>0.05), and the levels were significantly decreased after the treatment, with those in the treatment group lower than those of the control group [(NTXI:(32.22±5.45) vs (43.02±5.74)nmol/L, CTXI:(178.36±16.43) vs (208.34±19.22)ng/L, TRACP5b:(3.10±0.81) vs (3.86±0.85)ng/L, BGP:(2.16±0.46) vs (5.44±1.37)μg/L, BALP:(237.33±18.28) vs (270.43±21.12)U/L, all P<0.01]. The BMD was increased in both group, and that in the treatment group [(0.97±0.17)g/cm2] was significantly higher than that of the control group [(0.82±0.13)g/cm2, P<0.01]. Conclusion Alendronate sodium is of significant efficacy in the treatment of senile diabetes mellitus combined with osteoporosis, and is worthy of clinical promotion.
Close